Conference Coverage

VIDEO: iFR outperforms FFR in two major trials



– Instantaneous wave-free ratio (iFR) is the new evidence-based standard of care for invasive physiologic assessment of stable coronary lesions of intermediate angiographic severity, supplanting the older fractional flow reserve (FFR) technology, Matthias Gotberg, MD, said at the annual meeting of the American College of Cardiology.

He presented the potentially game-changing findings of the iFR-SWEDEHEART trial, one of two large randomized trials of iFR versus FFR presented at the conference, the other being the DEFINE-FLAIR study.

The virtually identical results of these two trials should encourage more interventional cardiologists to incorporate physiologic assessment of stable coronary lesions into their clinical practice instead of relying solely on anatomic assessment by angiography, which abundant evidence shows is insufficiently accurate in identifying hemodynamically significant lesions warranting revascularization.

FFR never really caught on because of its limitations. DEFINE-FLAIR and iFR-SWEDEHEART show that iFR overcomes those limitations, said Dr. Gotberg, director of the cardiac catheterization laboratory at Skane University Hospital in Lund, Sweden.

The two studies showed that iFR was noninferior to FFR in the 1-year composite endpoint of all-cause mortality, nonfatal MI, or unplanned revascularization. And iFR was associated with significantly shorter procedure times, less stent utilization, and markedly less patient discomfort because, unlike FFR, it doesn’t require administration of adenosine to induce hyperemia.

Indeed, in iFR-SWEDEHEART, which included more than 2,000 randomized patients in three Scandinavian countries, only 3% of the iFR group reported experiencing chest pain, dyspnea, or other forms of discomfort during their procedure, compared with 68% of the FFR group, Dr. Gotberg explains in this video interview.

The video associated with this article is no longer available on this site. Please view all of our videos on the MDedge YouTube channel.

Recommended Reading

TAVR can be performed safely within 30 days of PCI
MDedge Cardiology
FDA approves first dedicated bifurcation device to treat coronary bifurcation lesions
MDedge Cardiology
Can better operations improve CABG in women?
MDedge Cardiology
VIDEO: SURTAVI results ‘tremendously important’ for decision making
MDedge Cardiology
Older TAVR implant devices significantly less effective than newer ones in bicuspid AS patients
MDedge Cardiology